Buy HDFC Life Insurance Ltd For Target Rs 1,250 By Emkay Global Financial Services Ltd
The Board of Directors of HDFC Life has recommended the reappointment of Vibha Padalkar as MD and CEO for a term of 5 years starting 12-Sep-26, upon the conclusion of her current term, subject to shareholder approval in the upcoming AGM and approval by the IRDAI. As of 12-Sep-26, Padalkar will have completed 8 years as the MD and CEO of the company and 14 years and 1 month as a Whole-time Director. We view this recommendation as a vote of approval for Padalkar’s leadership by the Board, and a clear indication of continued faith in her management, despite relatively underwhelming share price performance of HDFCLIFE during her tenure. Notwithstanding the muted performance during her leadership, which was influenced by multiple factors beyond her control, an objective assessment of her leadership based on the company’s financial and operating outcomes over FY19-26 suggests an impressive performance across most parameters (including APE, retail APE market share, VNB, and EV per share compounding). The key exception is VNB margin, which in FY26 remained at the FY19 level, while most peers witnessed material expansion. Overall, we view the reappointment as a positive development for HDFCLIFE and await regulatory approval. A revival in growth remains key to a stock re-rating.
Board reaffirms faith in MD
By recommending Vibha Padalkar’s reappointment as MD & CEO of the company for a full 5-year term, the Board has expressed its confidence in her leadership. This also comes as an acknowledgment by the Board about her contributions as the key leader in the company (CFO and WTD until Sep-2018 and CEO since Sep-2018) during the decade of regulatory disruptions and macro headwinds such as Covid-19. Following the Board’s recommendation, the appointment will be subject to approval from both shareholders and the regulator. The regulatory approval is expected to provide much-needed clarity in a sector where there is ambiguity regarding the 15-year tenure limit, particularly, whether it applies only to the duration as MD or to the tenure as a Whole-time Director.
Muted share price performance overshadows operational successes
The muted share price performance of HDFCLIFE’s shares in recent years, including during Padalkar’s tenure as MD, along with weaker APE growth in FY26, overshadows a remarkable operational and financial performance over the past 7 years. During FY19- 26, HDFCLIFE, even after adjusting for the Exide Life acquisition, has outperformed both the industry and the private sector in retail WRP. When assessed against listed peers, it has performed well in terms of APE, VNB, and EV per share growth over this period.
The only parameter of underperformance has been VNB margin, which is largely explained by:
1) The Exide Life acquisition diluting the margin profile
2) Higher expenses to drive growth in open channels. The muted share price performance can also be partly attributed to the relatively high valuation premium ascribed to HDFCLIFE in FY18-19.
For More Emkay Global Financial Services Ltd Disclaimer http://www.emkayglobal.com/Uploads/disclaimer.pdf & SEBI Registration number is INH000000354
